Elite in Autosomal Recessive Hypotrichosis

Bark-lynn L. Lew

Seoul, KR 
Elite in Autosomal Recessive Hypotrichosis
Seoul, KR 
OverviewLocationsClinical Research

Overview

Bark-lynn Lew practices in Seoul, Republic of Korea. Lew is rated as an Elite expert by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Their top areas of expertise are Autosomal Recessive Hypotrichosis, Alopecia Areata, Atopic Dermatitis, and Vitiligo.

Their clinical research consists of co-authoring 91 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 38 articles and participated in 2 clinical trials in the study of Autosomal Recessive Hypotrichosis.

Locations

Seoul, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

91 Total Publications

Ethnic-Specific and UV-Independent Mutational Signatures of Basal Cell Carcinoma in Koreans.
Ethnic-Specific and UV-Independent Mutational Signatures of Basal Cell Carcinoma in Koreans.
Journal: International journal of molecular sciences
Published: May 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lew's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile